Galmed Pharmaceuticals News

Hepion Ends Phase 2 Study for NASH Drug Due to Cash Restraints

Seeking AlphaApr 20 05:10

Why PriceSmart Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket

Shares of PriceSmart, Inc. (NASDAQ:PSMT) rose sharply in today's pre-market trading as the company posted better-than-expected earnings for its second quarter. The company reported quarterly earnings

BenzingaApr 10 20:12

Madrigal Announces US Launch of NASH/MASH Drug Rezdiffra

Seeking AlphaApr 9 22:03

Why Esperion Therapeutics Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket

Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) shares rose sharply during today's pre-market trading after the company presented new data from CLEAR outcomes at ACC.24 highlighting value of NEX

BenzingaApr 8 17:15

Galmed Pharmaceuticals Ltd. (GLMD) Surges After Hours: An Unexpected Rally

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) concluded its Friday's trading session with a modest 2.8% gain, leaving investors to be cautiously optimistic. However, the post-closing activity took an unforeseen turn, with GLMD experiencing a remarkable 15% surge in after-hours trading. During the typically quieter after-hours session, GLMD's stock surged, capturing investors' attention. Trading volume spiked to ...

Stocks TelegraphApr 8 15:35

Galmed Pharmaceuticals Granted Nasdaq Extension

TipRanksMar 20 05:28

On March 19, Galmed Pharmaceuticals Got Letter From Nasdaq That Granted Co Additional 180 Calendar Day Period To Regain Compliance

On March 19, Galmed Pharmaceuticals Got Letter From Nasdaq That Granted Co Additional 180 Calendar Day Period To Regain Compliance

BenzingaMar 20 05:01

Inventiva Phase 2 Study for MASH Drug Meets Primary Endpoint

Seeking AlphaMar 19 05:45

The NASH pharmaceutical market is expected to exceed $48 billion by 2035, and companies such as Novo Nordisk (NVO.US) and Lily.US (LLY.US) will begin to deploy

According to international consulting firm Research Nester, the global non-alcoholic steatohepatitis (NASH) treatment market is expected to reach US$48.3 billion by 2035.

Zhitong FinanceMar 18 09:00

NASH Drug Market Expected to Surpass $48B by 2035

Seeking AlphaMar 17 00:57

Galmed Announces Grant of New Patent for the Combination of Aramchol With Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic...

PR NewswireMar 15 21:00

Sector Update: Health Care Stocks Higher Late Tuesday Afternoon

Health care stocks advanced late Tuesday afternoon, with the NYSE Health Care Index adding 0.7% and the Health Care Select Sector SPDR Fund (XLV) up 0.6%. The iShares Biotechnology ETF (IBB) fell 0.7%

MT NewswiresNov 22, 2023 04:45

Sector Update: Health Care

Health care stocks advanced late Tuesday afternoon with the NYSE Health Care Index adding 0.7% and the Health Care Select Sector SPDR Fund (XLV) up 0.6%. The iShares Biotechnology ETF (IBB) fell 0.7%.

MT NewswiresNov 22, 2023 04:32

Galmed Announces A Delay Of At Least Six Months In The Initiation Of Its Primary Sclerosing Cholangitis (PSC) Phase 2a Study

Galmed Announces A Delay Of At Least Six Months In The Initiation Of Its Primary Sclerosing Cholangitis (PSC) Phase 2a Study

BenzingaNov 21, 2023 05:34

Galmed Announces a Delay in the Initiation of Its Primary Sclerosing Cholangitis (PSC) Phase 2a Study

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) announced today a delay of at least 6 months in the initiation of its Primary Sclerosing Cholangitis (PSC) Ph 2a Study.

PR NewswireNov 21, 2023 05:32

Galmed Pharmaceuticals Has Been Granted European Patent Number EP3538158 Titled "Treatment For Fibrosis (Including Methods For Inhibition Of Fibrotic Disorders And Hepato-Fibrotic Conditions Associated With NAFLD And NASH)"

Galmed Pharmaceuticals Has Been Granted European Patent Number EP3538158 Titled "Treatment For Fibrosis (Including Methods For Inhibition Of Fibrotic Disorders And Hepato-Fibrotic Conditions Associate

BenzingaOct 2, 2023 22:24

Global Nonalcoholic Steatohepatitis (NASH) Therapeutics Market 2023-2035: Key Players Pfizer, Novo Nordisk, and Galmed Pharmaceuticals Drive Innovation in the NASH Therapeutics Market

Yahoo FinanceSep 28, 2023 18:03

Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis

PRNewswireSep 26, 2023 20:30

Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification

TEL AVIV, Israel, Sept. 22, 2023 /PRNewswire/ —Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases,

PR NewswireSep 23, 2023 04:05

Drugmakers Still Chasing Potentially Lucrative NASH Market, Despite Setbacks

Seeking AlphaAug 15, 2023 01:19